Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-08-03
2010-12-07
Kolker, Daniel (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C514S012200
Reexamination Certificate
active
07846438
ABSTRACT:
The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.
REFERENCES:
patent: 5225538 (1993-07-01), Capon et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 2002/0068696 (2002-06-01), Wood et al.
patent: 2003/0219860 (2003-11-01), Tschopp et al.
patent: 2004/0142423 (2004-07-01), Tada et al.
patent: 2007/0186296 (2007-08-01), Gao et al.
patent: 0990703 (2000-04-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 98/01554 (1998-01-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/13078 (1999-03-01), None
patent: WO 99/20644 (1999-04-01), None
patent: WO 99/33967 (1999-07-01), None
patent: WO 99/33980 (1999-07-01), None
patent: WO 99/37818 (1999-07-01), None
patent: WO 00/01817 (2000-01-01), None
patent: WO 2006/017673 (2000-01-01), None
patent: WO 00/49149 (2000-08-01), None
patent: WO 00/53758 (2000-09-01), None
patent: WO 01/38526 (2001-05-01), None
patent: WO 01/58954 (2001-08-01), None
patent: WO 01/68848 (2001-09-01), None
patent: WO 01/93983 (2001-12-01), None
patent: WO 02/00690 (2002-01-01), None
patent: WO 02/08284 (2002-01-01), None
patent: WO 02/08288 (2002-01-01), None
patent: WO 03/013578 (2003-02-01), None
patent: WO 2005/058028 (2005-06-01), None
Purves, Dale, et al (Eds.), Neuroscience, 2001, Sinauer Associates, Inc., 2nd Edition, pp. 75, 367, 400, 403, 554, 555 and 679.
Vickers. A vaccine against Alzheimer's disease: developments to date. Drugs Aging 2002; 19(7):487-94.
Stokes et al. (Experimental modeling of human spinal cord injury: a model that crosses the species barrier and mimic the spectrum of human cytopathology, Spinal Cord 40: 101-109, 2002.
Talac et al. Animal models of spinal cord injury for evaluation of tissue engineering treatment strategies, Biomaterials 25: 1505-1510, 2004.
Mills et al. Strain and model differences in behavioral outcomes after spinal cord injury in rat,J. Neurotrauma Aug;18(8):743-56, 2001.
Mautes et al. Vascular events after spinal cord injury: contribution to secondary pathogenesis. Phys Ther. Jul. 2000;80(7):673-87.
Helmuth. New therapies. New Alzheimer's treatments that may ease the mind. Science. Aug. 23, 2002;297(5585):1260-2.
Rosenberg, L.J. and Warthall, J. R., “Time Course Studies on the Effectiveness of Tetrodotoxin in Reducing Consequences of Spinal Cord Contusion,”J. Neurosci. Res.66:191-202, Wiley-Liss, Inc. (2001).
International Search Report for International Patent Application No. PCT/US05/27773, United States Patent and Trademark Office, Alexandria, VA, mailed on Dec. 4, 2006.
Written Opinion of the International Search Authority for International Patent Application No. PCT/US05/27773, United States Patent and Trademark Office, Alexandria, VA, mailed on Dec. 4, 2006.
Aggarwal, B.B., and Natarajan, K., “Tumor Necrosis Factors: Developments During the Last Decade,”Eur. Cytokine Netw.7: 93-124, John Libbey Eurotext Ltd. (1996).
Banner, D.W., et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation,”Cell73:431-445, Cell Press (1993).
Bazzoni, F., and Beutler, B., “The Tumor Necrosis Factor Ligand and Receptor Families,”N. Engl. J. Med.334: 1717-1725, Massachusetts Medical Society (1996).
Bodmer, J.-L., et al., “The molecular architecture of the TNF superfamily,”Trends Biomed. Sci.27:19-26, Elsevier Science Ltd. (2002).
Bork, P., “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,”Genome Res.10:398-400, Cold Spring Harbor Laboratory Press (2000).
Copray, S., et al., Deficient p75 Low-affinity Neurotrophin Receptor Expression Exacerbates Experimental Allergic Encephalomyelitis in C57/BL6 Mice,J. Neuroimmunol.148: 41-53, Elsevier/Holland (Mar. 2004).
Eason, J.D., et al., “Evaluation of Recombinant Human Soluble Dimeric Tumor Necrosis Factor Receptor for Prevention of OKT3-associated Acute Clinical Syndrome,”Transplantation61:224-228 (1996).
Eby, M.T., et al., “TAJ, a Novel Member of the Tumor Necrosis Factor Receptor Family, Activates the c-Jun N-terminal Kinase Pathway and Mediates Caspase-independent Cell Death,”J. Biol. Chem.275:15336-15342, The American Society for Biochemistry and Molecular Biology, Inc. (2000).
Eggermont, A.M., et al., “Isolated Limb Perfusion with High-Dose Tumor Necrosis Factor-Alpha in Combination With Interferon-Gamma and Melphalan for Nonresectable Extremity Soft Tissue Sarcomas: A Multicenter Trial,”J. Clin. Oncol14:2653-2665, Springer (1996).
Feldmann, M., et al., “Role of Cytokines in Rheumatoid Arthritis,”Annu. Rev. Immunol.14:397-440, Annual Reviews (1996).
Fournier, A.E., et al., “Identification of a Receptor Mediating Nogo-66 Inhibition of Axonal Regeneration,”Nature409:341-346, Nature Publishing Group (2001).
Giehl, K.M., et al., “Endogenous Brain-derived Neurotrophic Factor and Neurotrophin-3 Antagonistically Regulate Survival of Axotomized Corticospinal Neurons In Vivo,”J. Neurosci.21: 3492-3502, Society for Neuroscience (2001).
Green, D.R., and Ware, C.F., “Fas-Ligand: Privilege and Peril,”Proc. Natl. Acad. Sci.USA 94:5986-5990, National Academy of Sciences (1997).
Hisaoka, T., et al., “Expression of a member of tumor necrosis factor receptor superfamily, TROY, in the developing mouse brain,”Develop. Brain Res.143:105-109, Elsevier Science B.V. (Jun. 2003).
Kojima, T., et al., “TROY, a Newly Identified Member of the Tumor Necrosis Factor Receptor Superfamily, Exhibits a Homology with Edar and Is Expressed in Embryonic Skin and Hair Follicles,”J. Biol. Chem.275:20742-20747, The American Society for Biochemistry and Molecular Biology, Inc. (2000).
Mandemakers, W.J. and Barres, B.A., “Axon Regeneration: It's Getting Crowded at the Gates of TROY,”Curr. Biol.15:R302-R305, Cell Press (Apr. 2005).
Mi, S., et al., “Lingo-1 is a Component of the Nogo-66 Receptor/p75 Signaling Complex,”Nat. Neurosci.7:221-228, Nature Publishing Group (Mar. 2004).
Mikayama, T., et al., “Molecular Cloning and Functional Expression of a cDNA Encoding Glycosylation-Inhibiting Factor,”Proc. Natl. Acad. Sci.USA 90:10056-10060, National Academy of Sciences (1993).
Robertson, N.G., et al., “Isolation of Novel and Known Genes from a Human Fetal Cochlear cDNA Library Using Subtractive Hybridization and Differential Screening,”Genomics23:42-50, Academic Press, Inc. (1994).
Rutishauser, U., and Jessell, J.M., Cell Adhesion Molecules in Vertebrate Neural Development,Physiol. Rev.68:819, American Physiological Society (1988).
Shao, Z., et al., “TAJ/TROY, an Orphan TNF Receptor Family Member, Binds Nogo-66 Receptor 1 and Regulates Axonal Regeneration,”Neuron45:353-359, Elsevier Inc. (Feb. 2004).
Skolnick, J., and Fetrow, J.S., “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Area,”Trends Biotechnol.18:34-39, Elsevier Science Publishers (2000).
Smith, C.A., et al., “CD30 Antigen, a Marker for Hodgkin's Lymphoma, is a Receptor Whose Ligand Defines an Emerging Family of Cytokines with Homology to TNF,”Cell73:1349-1360, Cell Press (1993).
Smith, C.A., et al., “The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death,”Cell76:959-962, Cell Press (1994).
Smith, G.L., “Virus Strategies for Evasion of the Host Response to Infection,”Trends Microbiol.2:81-88, Elsevier Trends Journals (1994).
Song, X.Y., et al.,“Suppression of p75NTR Does Not Promote Regeneration of Injured Spinal Cord in Mice,”J. Neurosci.24:542-546, Society for Neuroscience (Jan. 2004).
van Dullemen, H.M., et al., “Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2),”Gastroenter
Browning Jeffrey L.
Mi Sha
Biogen Idec MA Inc.
Emch Gregory S
Kolker Daniel
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Methods of promoting neurite outgrowth with soluble TAJ... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of promoting neurite outgrowth with soluble TAJ..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of promoting neurite outgrowth with soluble TAJ... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181825